Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its activity in patients without antiretroviral therapy is unknown. This study will test the efficacy and safety of IL-2 in naïve patients with a CD4 count between 300 and 500/m3.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
• Collaborator: Chiron Corporation
• Treatments: Interleukin-2

Criteria

Inclusion Criteria:

• Adult patients with proven HIV-1-infection

• No prior exposition to antiretrovirals

• CD4 cell count between 300 and 500/mm3

• Signed written inform consent

Exclusion Criteria:

• Pregnancy